Veracyte Inc Market Cap ($3.38 Billion)
Market Cap & Net Worth: Veracyte Inc (VCYT)
Veracyte Inc market cap. Veracyte Inc (NASDAQ:VCYT) has a market capitalization of $3.38 Billion ($3.38 Billion) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4439 globally and #1553 in its home market, demonstrating a 2.23% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Veracyte Inc's stock price $49.00 by its total outstanding shares 80390731 (80.39 Million). Also see Veracyte Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Veracyte Inc Market Cap History (2015–2026)
Veracyte Inc market cap history from 2015 to 2026. Data shows growth from $578.81 Million to $3.94 Billion (20.17% CAGR). Check Veracyte Inc stock price for real-time trading data and today's change.
Index Memberships
Veracyte Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$1.05 Trillion | 0.32% | #27 of 30 |
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.13% | #119 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.01% | #515 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.18% | #76 of 263 |
Weight: Veracyte Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Veracyte Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Veracyte Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Veracyte Inc equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
6.54x
Veracyte Inc's market cap is 6.54 times its annual revenue
Latest Price to Earnings (P/E) Ratio
51.01x
Veracyte Inc's market cap is 51.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $622.22 Million | $65.08 Million | -$31.36 Million | 9.56x | N/A |
| 2017 | $524.95 Million | $71.95 Million | -$31.00 Million | 7.30x | N/A |
| 2018 | $1.01 Billion | $92.01 Million | -$23.00 Million | 10.99x | N/A |
| 2019 | $2.24 Billion | $120.37 Million | -$12.60 Million | 18.65x | N/A |
| 2020 | $3.93 Billion | $117.48 Million | -$34.91 Million | 33.49x | N/A |
| 2021 | $3.31 Billion | $219.51 Million | -$75.56 Million | 15.09x | N/A |
| 2022 | $1.91 Billion | $296.54 Million | -$36.56 Million | 6.43x | N/A |
| 2023 | $2.21 Billion | $361.05 Million | -$74.40 Million | 6.13x | N/A |
| 2024 | $3.18 Billion | $445.76 Million | $24.14 Million | 7.14x | 131.89x |
| 2025 | $3.38 Billion | $517.14 Million | $66.35 Million | 6.54x | 51.01x |
Competitor Companies of VCYT by Market Capitalization
Companies near Veracyte Inc in the global market cap rankings as of November 4, 2026. Also see Veracyte Inc (VCYT) total assets for a full breakdown of the balance sheet.
Key companies related to Veracyte Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #143 globally with a market cap of $161.03 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #493 globally with a market cap of $54.62 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #539 globally with a market cap of $50.18 Billion USD ( CN¥342.92 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $682.65 |
| #143 | Danaher Corporation | NYSE:DHR | $161.03 Billion | $227.97 |
| #493 | Natera Inc | NASDAQ:NTRA | $54.62 Billion | $378.92 |
| #539 | WuXi AppTec Co Ltd | SHG:603259 | $50.18 Billion | CN¥138.65 |
Market Capitalization of Veracyte Inc (2015–2026)
Market capitalization of Veracyte Inc from 2015 to today. Between 2015 and today, Veracyte Inc's market cap moved from $578.81 Million to $ 3.94 Billion, with a yearly change of 20.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.94 Billion | +16.39% |
| 2025 | $3.38 Billion | +6.31% |
| 2024 | $3.18 Billion | +43.95% |
| 2023 | $2.21 Billion | +15.93% |
| 2022 | $1.91 Billion | -42.40% |
| 2021 | $3.31 Billion | -15.82% |
| 2020 | $3.93 Billion | +75.29% |
| 2019 | $2.24 Billion | +121.94% |
| 2018 | $1.01 Billion | +92.65% |
| 2017 | $524.95 Million | -15.63% |
| 2016 | $622.22 Million | +7.50% |
| 2015 | $578.81 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Veracyte Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.38 Billion USD |
| MoneyControl | $3.38 Billion USD |
| MarketWatch | $3.38 Billion USD |
| marketcap.company | $3.38 Billion USD |
| Reuters | $3.38 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more